tag@treatmentactiongroup.org

Home

Statement on the Introduction of the House Companion to the Cure Hepatitis C Act

  • Adam Ortega

Treatment Action Group (TAG) welcomes the introduction of the House companion to the Cure Hepatitis C Act (S.1941) and applauds Representatives Diana DeGette (D-CO), Mariannette Miller-Meeks (R-IA), Hank Johnson (D-GA), and Don Bacon (R-NE) for advancing bipartisan legislation to eliminate hepatitis C in the United States. We are particularly encouraged that the House bill removes the immigration-based eligibility restrictions contained in Section 10 of the Senate version — an important improvement that brings the legislation closer to the public health principles necessary to achieve hepatitis C virus (HCV) elimination in the United States in our lifetimes.

Read more

Research Toward a Cure Trials

  • Jason Kirk

Ending HIV requires sustained research. TAG’s July 2026 cure trials update tracks clinical studies worldwide, helping advocates, researchers, and communities follow progress toward a cure.

Read more

Treatment Action Group Comment on the Proposed Rule “Regulation for Federal Financial Assistance” (OMB-2026-0034)

  • Adam Ortega

Treatment Action Group (TAG) has submitted formal comments opposing a proposed rule from the White House Office of Management and Budget (OMB) that would overhaul how federal research grants are awarded and managed. Under the proposed rule changes, scientific experts would still review research applications, but political appointees would have final authority to approve, deny, or cancel awards based on alignment with the administration's priorities.

Read more

Why So Long? A Call for a More Humane Tuberculosis Treatment and Meaningful Community Engagement

  • Adam Ortega

Poetry can be used as a form of public health. In a recently written poem, LAT CAB member Bakyt Myrzaliev speaks about the trials and tribulations of tuberculosis treatment – writing passionately and inquisitively about side effects, the high burden of countless pills, and ultimately calling for investments into newer forms of treatment. Treatment Action Group (TAG) and the African Community Advisory Board (AfroCAB) formed the Long-Acting Technologies Community Advisory Board (LAT CAB) to implement meaningful, equitable solutions and research to serve communities that need them the most. LAT CAB is a dedicated community body that will advance LAT research and uptake under the Unitaid-funded LONGEVITY project.

Read more

Webinar: Implementing the 4-month HPMZ Regimen: Experience, Tools, and Next Steps

  • Adam Ortega

The WHO Global TB Program's Accelerator Platform for Novel TB Regimens held its 12th meeting to examine the four-month HPMZ (isoniazid, rifapentine, moxifloxacin, pyrazinamide) regimen for tuberculosis treatment, covering country experiences, implementation tools, and next steps for rollout. Despite the World Health Organization's (WHO) 2022 recommendation, implementation has remained limited, with challenges such as high pill burden and medicine costs cited as potential barriers.

Read more

Community Research Advisors Group (CRAG) Consultant

  • Adam Ortega

Treatment Action Group (TAG) is seeking a consultant to coordinate and strengthen the work of the Community Research Advisors Group (CRAG), one of the longest-running community advisory boards in tuberculosis (TB) research.

Read more

TAG Statement: OMB Proposal Would Turn Federal Grants Into a Political Tool

  • Adam Ortega

The White House Office Of Management and Budget (OMB) under the direction of Russell Vought is seeking a regulatory blessing to use Federal grant funding as a tool for political extortion, violation of due process, and further undermining of scientific integrity. Targets include scientists, institutions, organizations, States, cities, and other recipients who might fail an extreme right wing, Christian nationalist, anti-science political litmus test. 

Read more

Community and Civil Society Engagement Case Studies

  • Adam Ortega

The ASCENT DR-TB project, funded by Unitaid and led by the KNCV Tuberculosis Foundation, aims to improve access to shorter, safer and more effective treatment regimens for drug-resistant TB (DR-TB) and comprehensive, person-centered packages of quality care.

Read more
Back To Top